Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Nuclear Envelope-Targeted Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TMPO/LAP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMPO/LAP2 Alpha/Beta Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Soluble nucleoplasmic domains. |
View TMPO Products |
| Gene Delivery | TMPO/LAP2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View TMPO Products |
| Benchmark Ab | Anti-TMPO/LAP2 Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View TMPO Products |
| Validator | TMPO/LAP2 siRNA Set For knockdown verification in functional tumor assays. |
View TMPO Products |
| Related Target A | BANF1 (BAF) Essential binding partner of TMPO/LAP2; critical for nuclear assembly and chromatin organization. |
View BANF1 Products |
| Related Target B | LMNA (Lamin A/C) Interacts directly with LAP2 alpha; key node in laminopathies and nuclear envelope stability. |
View LMNA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nuclear protein extraction & solubility | Recombinant soluble fragments (nucleoplasmic domains) optimized for high stability and solubility without detergents. |
| Protein-protein interaction (PPI) screening | Sequence-verified binding domains (LAP2-constant region) expressed in eukaryotic systems to preserve native-like folding. |
| Lack of Controls | High-affinity recombinant benchmark antibodies validated for nuclear localization assays. |
| False Positives | Target-specific siRNA pool included for phenotypic rescue and specificity verification. |
Live TMPO/LAP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the nuclear envelope, particularly the Thymopoietin (TMPO) / Lamina-Associated Polypeptide 2 (LAP2) complex, represents an emerging frontier in oncology. TMPO encodes multiple isoforms (alpha, beta, gamma) that play pivotal roles in nuclear architecture, chromatin organization, and cell cycle regulation. LAP2 beta is an inner nuclear membrane protein, while LAP2 alpha localizes to the nucleoplasm. Overexpression of TMPO/LAP2 is strongly correlated with poor prognosis in glioblastoma, colorectal cancer, and hematological malignancies.
The race for TMPO/LAP2 therapeutics is intensifying, with major players shifting focus from traditional global chemotherapies to targeted small-molecule inhibitors of protein-protein interactions (such as the LAP2-BAF or LAP2-Lamin interactions) and PROTAC-mediated degradation. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the TMPO-barrier-to-autointegration factor (BAF) complex to selectively induce mitotic catastrophe in rapidly dividing cancer cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / PPI Inhibitors | Academic Medical Centers, Biotech Startups | Glioblastoma, Colorectal Cancer | High-throughput screening assays requiring pure, soluble TMPO nucleoplasmic domains. |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Hematological Malignancies, Solid Tumors | Ubiquitination assays requiring full-length or domain-specific TMPO recombinant proteins. |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Refractory Solid Tumors | Lentivirus-mediated rescue lines and validated siRNA control panels. |